Definium Therapeutics Quarterly Income Statement
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
36.90+2.72 (+7.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Definium Therapeutics revenue and earnings
Definium Therapeutics reported a net loss of $159.0 million, compared with a loss of $42.7 million a year earlier. Diluted earnings per share came in at -$1.44.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 75.08M | 59.22M | 47.58M | 45.67M | 40.90M | 32.16M | 32.46M | 24.79M | 24.46M | 22.20M | 22.20M | 21.62M |
| Research & Development | 48.66M | 41.48M | 33.52M | 30.98M | 29.81M | 23.36M | 21.76M | 17.19M | 14.64M | 11.71M | 11.55M | 13.20M |
| Operating Income | -75.08M | -59.22M | -47.58M | -45.67M | -40.90M | -32.16M | -32.46M | -24.79M | -24.46M | -22.20M | -22.20M | -21.62M |
| Interest Expense | 1.23M | 1.25M | 1.27M | 1.27M | 2.34M | 602.00K | 656.00K | 727.00K | 466.00K | 434.00K | 439.00K | 328.00K |
| Other Income (Expense) | -83.91M | -17.88M | -2.86M | -21.60M | -1.84M | 8.81M | -2.28M | 11.11M | 18.60M | -32.20M | -1.66M | 3.69M |
| Net Income | -158.99M | -77.10M | -50.44M | -67.27M | -42.74M | -23.35M | -34.74M | -13.68M | -5.85M | -54.40M | -23.86M | -17.92M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.44 | -0.71 | -0.51 | -0.78 | -0.50 | -0.27 | -0.14 | -0.18 | -0.08 | -1.14 | -0.58 | -0.45 |
| EPS (Diluted) | -1.44 | -0.71 | -0.43 | -0.78 | -0.50 | -0.35 | 0.13 | -0.27 | -0.26 | -1.14 | -0.58 | -0.45 |
| Shares Outstanding (Basic) | 110.68M | 108.79M | — | 85.89M | 85.35M | 85.07M | — | 77.91M | 71.91M | 47.86M | — | 39.72M |
| Shares Outstanding (Diluted) | 110.68M | 108.79M | — | 85.89M | 85.35M | 87.09M | — | 80.24M | 75.30M | 47.86M | — | 39.72M |
This table shows 12 quarterly periods of Definium Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DFTX's reporting calendar. What is a income statement?